cleared a growing population of S. aureus, suggesting that the strain secretes a compound that causes the breakdown (lysis) of S. aureus. Using a library of S. lugdunensis mutants in which individual genes had been knocked out, the researchers identified a single mutant that was unable to inhibit S. aureus. Studying this mutant enabled identification of the compound responsible for S. aureus inhibition -a peptide antibiotic that the authors named lugdunin. Zipperer and colleagues' findings suggest that treatment with S. lugdunensis (or use of lugdunin) may be a valuable tool for the prevention of S. aureus colonization in the clinic.
It may seem surprising that a member of the human microbiota -the community of bacteria that inhabits the body -produces an antibiotic. However, the microbiota is composed of more than a thousand species 4 , many of which compete for space and nutrients, and the selective pressure to eliminate bacterial neighbours is high. This intense competition can be observed by surveying patterns of bacterial communities in which the presence of a particular species is negatively associated with the presence of other species 5 . One probable mechanism for these negative interactions is the production of antibiotics. Although conventional antibiotic discovery has focused on mining compounds from soil-living bacteria, genome-wide analysis of the human microbiome has identified many gene clusters that encode enzymes associated with antibiotic production, such as polyketide synthases or non-ribosomal peptide synthetases. However, only a few such antibiotics have been characterized in the laboratory: strain-specific bacterial inhibitory molecules called bacteriocins 6, 7 ; fairly large peptide antibiotics called lantibiotics 8 ; and the antibiotic lacto cillin, which is active against several patho genic bacteria 9 . Until now, evidence linking these compounds to the competitive advantage that they may confer has been lacking. The current study fills this gap.
Zipperer and colleagues found that lugdunin is active against several pathogens, including MRSA strains and Enterococcus bacteria that are resistant to the antibiotic vancomycin -and the bacteria treated with lugdunin did not develop resistance to it. In both in vitro and in vivo studies in mice, the ability of S. lugdunensis to outcompete S. aureus depends on the presence of a functional lugdunin biosynthesis pathway.
When the authors analysed 187 hospitalized patients, they found that S. aureus colonization was just 5.9% in individuals who carry S. lugdunensis, compared with 34.7% in individuals without S. lugdunensis. When produced by a bacterium that occupies a confined niche, it is clear that lugdunin and similar antibiotics have considerable power to influence bacterial community structure. Given that S. lugdunensis is present in only around 10% of the population and S. aureus is found in about 30% of the population, there are probably more antibiotics yet to be discovered that are responsible for S. aureus colonization resistance.
Lugdunin was found to be effective as a topical agent (applied to the surface) for treating an S. aureus skin infection in mice. Considering that lugdunin can inhibit the synthesis of major biopolymers (proteins, DNA and peptidoglycans) in S. aureus, it is probably a membrane-acting antibiotic, which would be challenging to develop into a systemic therapeutic because such compounds also tend to disrupt membranes of mammalian cells.
The method of discovery of lugdunin reported by Zipperer and colleagues provides a general approach to investigating antibioticdriven colonization resistance of the human microbiota against pathogens (Fig. 1) . By combining genomic and co-occurrence data, bacteria can be identified that are negatively correlated with the presence of a pathogen and that have the potential to produce antibiotics. These organisms, or the antibiotics they produce, might serve as drug-discovery leads. ■
In retrospect

Thirty-five years of endless cell potential
Pluripotent cells have the potential to differentiate into any cell type in the body. Their isolation and propagation from mouse embryos was pivotal for advances in understanding human development and disease. (Fig. 1) .
M . A Z I M S U R A N I
In the 1950s, it was reported 3 that mice, like humans, could develop testicular tumours called teratomas, which were derived from germ-cell precursors (precursors of eggs or, in this case, sperm) and contained various differentiated cell types not normally found in testes. The teratomas also contained embryonic carcinoma (EC) cells, which had key attributes of pluripotency.
However, EC cells could not efficiently differentiate into normal tissues if they were injected into blastocysts. In particular, their differentiation into sperm or eggs was not observed, meaning that EC cells could not be used to generate strains of mice that could pass experimentally induced mutations on to their offspring -a major goal of research into pluripotency. This shortcoming encouraged efforts to find other sources of pluripotent stem cells.
Evans and Kaufman established ES cells directly from mouse blastocysts that had been prevented from undergoing further development, for example by treating the mothers with steroids. Meanwhile, Martin grew inner cell masses from late-stage blastocysts using culture media in which EC cells had been grown previously, in the hope that the EC cells might have released factors conducive to the growth of ES cells. Both studies were successful, leading to the first isolations of blastocyst-derived ES cells that could be maintained indefinitely in vitro.
ES-cell isolation had an immediate and profound impact on the study of mammalian development. Unlike EC cells, ES cells could reliably give rise to germ cells 4 , 
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making it possible to introduce specific genetic mutations into mouse strains. To briefly outline the process, ES cells are genetically engineered to harbour a specific mutation, and are then transplanted into a host blastocyst. The resulting embryo is a chimaera -some of its cells will contain the mutation, others will not. If germ cells carry the mutation, it can be passed to the offspring. The consequences of the mutation can then be examined in detail.
A great many mutant mouse strains have been generated in this way, enabling detailed analyses of the functions of individual genes under physiological conditions. Genes vital for embryonic development, especially those that establish the body plan, were mutated to study their precise role 5 . Moreover, human diseases could be modelled in other mammals. For example, a gene that causes cystic fibrosis in humans was mutated in mouse ES cells 6 , and mice carrying this mutant gene were then created to provide an animal model for the disease.
The development of large-scale mutation strategies such as gene traps (in which mutations are introduced into DNA at random through the insertion of a genetic construct that produces a 'reporter' protein) led to the production of mutation libraries -a useful resource of cells from which mice carrying particular mutations could be made. Before the isolation of ES cells, all such research was limited by the availability of naturally occurring mutations. But today, any gene can be investigated at will.
Following this impressive progress, attention shifted to humans. In 1998, human ES (hES) cells were eventually isolated 7 . Although not molecularly identical to mouse ES cells, hES cells nonetheless possess the key properties of pluripotency -self-renewal and an ability to differentiate into diverse lineages. Moreover, they provide opportunities for studying early human development.
Ethical considerations prevent hES cells from being used for germline therapy, in which genetic changes would be introduced into hESderived germ cells with the aim of correcting faulty genes. However, two studies published last year 8, 9 showed that germ-cell precursors can be derived from hES cells, paving the way for studies of human germ cells and indicating that it might one day be possible to make sperm and eggs in culture. Some key genes involved in the induction of human germ-cell precursors, however, are not involved in mouse germ cells 8, 9 . Thus, these studies, with many others, have revealed key differences between mouse and human development.
Studies on ES cells also defined the four key regulatory genes that control pluripotency, which in 2006 led to a major advance -the conversion of differentiated cells into induced pluripotent stem (iPS) cells [10] [11] [12] . iPS cells have since been derived from patients and differentiated into specific cell types, to simulate the initiation and progression of disease in culture. Moreover, iPS cells are currently being used to develop in vitro models for testing potential therapeutic compounds to treat diseases such as Alzheimer's. Human ES cells and iPS cells might some day be used as part of cell-replacement therapies in diseased tissues, although the greatest advances in their use will initially probably be in basic research and in screens for therapeutic agents.
One useful feature of ES cells is their ability to self-organize into differentiated tissues and to assemble into structures that have recognizable attributes of organs. In the past decade, this quality has been exploited to produce synthetic organs called organoids in culture. So far, human organoids have been generated that model the brain, intestine, liver and kidney, among others [13] [14] [15] . More-advanced 3D models that approximate physiological settings are likely to be developed in the future using tissue-engineering methods. Attempts are now under way to generate human organs in animals, by incorporating hES cells into blastocysts from other species. This might alleviate the unmet demand for organs for transplantation.
Advances made following the isolation of pluripotent ES cells have coincided with progress in other technologies, such as live imaging, single-cell analysis and genome editing 16 . When combined to study human organoids, these approaches will allow analysis of the outcomes of increasingly sophisticated manipu lations of genes and of the genetic elements that regulate their expression. Such studies will provide unprecedented understanding of how genes individually and collectively regulate human development, and how such regulation can go awry.
The history of ES cells shows how basic research has led to revolutionary advances. The future presents us with endless opportunities to explore how a single cell transforms into a multicellular adult organism. ■ 
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